<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2007-7459</journal-id>
<journal-title><![CDATA[Horizonte sanitario]]></journal-title>
<abbrev-journal-title><![CDATA[Horiz. sanitario]]></abbrev-journal-title>
<issn>2007-7459</issn>
<publisher>
<publisher-name><![CDATA[Universidad Juárez Autónoma de Tabasco, División Académica de Ciencias de la Salud]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2007-74592019000100007</article-id>
<article-id pub-id-type="doi">10.19136/hs.a18n1.2514</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[La Farmacovigilancia en Cuba y la Infranotificaciones de Reacciones Adversas a los Medicamentos]]></article-title>
<article-title xml:lang="en"><![CDATA[Pharmacovigilance in Cuba and Adverse Reactions to Drugs Underreporting]]></article-title>
<article-title xml:lang="pt"><![CDATA[Farmacovigilância em Cuba e Subnotificações de Reções Adversas a Medicamentos]]></article-title>
<article-title xml:lang="fr"><![CDATA[Pharmacovigilance à Cuba et Sous-déclaration des Réactions Indésirables aux Médicaments]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Tarragó Portelles]]></surname>
<given-names><![CDATA[Sury Saday]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gravier Hernández]]></surname>
<given-names><![CDATA[Rosario]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gil del Valle]]></surname>
<given-names><![CDATA[Lizette]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Departamento de Investigaciones Farmacológicas  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Departamento de Investigaciones Farmacológicas  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Departamento de Investigaciones Farmacológicas  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>04</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>04</month>
<year>2019</year>
</pub-date>
<volume>18</volume>
<numero>1</numero>
<fpage>7</fpage>
<lpage>15</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2007-74592019000100007&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2007-74592019000100007&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2007-74592019000100007&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Objetivo:  Efectuar una revisión de los conocimientos sobre la Farmacovigilancia, el suministro de información sobre sospechas de RAM, que es tanto un deber moral para el médico y otros profesionales de salud como un aspecto de la atención al paciente y la infranotificación de estos reportes.  Material y métodos:  La revisión fue realizada en las bases de datos LILACS, PAHO, SciELO, EMBASE, PubMed e Infomed, los motores de búsqueda Google y Google Scholar donde se colocaron palabras claves para la búsqueda de la información en artículos originales, tesis, otros artículos de revisión bibliográfica y revistas de elevado índice de citación publicados desde 1937 a 2017, en los idiomas español o inglés.  Resultados:  Se identificaron 100 artículos, de los cuales 30 fueron seleccionados como útiles verificados para actualizar los conceptos relacionados con las disciplinas de Farmacovigilancia. En la práctica clínica existen varios factores que pueden dificultar la detección de las RAM y como consecuencia contribuir a la infranotificación.  Conclusiones:  La infranotificación en Farmacovigilancia es una realidad mundial, observándose que la mayoría de las publicaciones analizadas que proceden de Europa (Alemania, España y Reino Unido) y en países de América Latina como Colombia, reconocen bajos índices de notificación.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Object:  The article proposes a pharmacovigilance knowledge review, the provisión of information on suspicion of AMR, which is both a moral duty for the doctor and other health professionals and an aspect of patient care and the underreporting of them.  Materials and methods:  The review was carried out in the databases LILACS, PAHO, SciELO, EMBASE, PubMed and Infomed, the Google search engines and Google Scholar where keywords were placed for the search of the information in original articles, theses, other articles of bibliographic review and high citation index journals published from 1937 to 2017, in Spanish or English.  Results:  Consequently 100 articles were identified, 30 of which were selected as verified tools to update the concepts related to Pharmacovigilance discipline. There are several factors in clinical practice that can hinder the detection of ADR and it could contribute to under-reporting.  Conclusión:  In pharmacovigilance the under-reporting is a global reality, noting that most of the analyzed publications come from Europe (Germany, Spain and the United Kingdom) and in Latin American countries such as Colombia, recognize low reporting rates.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo  Objetivo:  O artigo propõe uma revisao de literatura sobre farmacovigilancia, fornecendo informações sobre suspeitas de RAM, que é um dever moral para os médicos e outros profissionais de saúde como um aspecto da assistencia ao doente e subnotificação desses relatórios.  Materiais e métodos:  A pesquisa foi realizada nas bases de dados LILACS, PAHO, SciELO, EMBASE, PubMed e Infomed, nos motores de busca Google e Google Scholar, onde foram colocadas as palavras-chave para encontrar as informações em artigos originais, teses, outros artigos de revisão bibliográfica e de revistas de alto índice de citação publicados de 1937 a 2017, em espanhol ou inglês.  Resultados:  Foram identificados 100 artigos, dos quais 30 foram selecionados como instrumentos importantes para atualização dos conceitos relacionados á disciplina de farmacovigilancia. Na prática clínica, existem vários fatores que podem dificultar a detecção de RAM e, consequentemente, contribuir para uma subnotificação  Conclusão:  Na farmacovigilãncia, a subnotificação é uma realidade mundial, observando que a maioria das publicações analisadas provenientes da Europa (Alemanha, Espanha e Reino Unido) e dos países latino-americanos como a Colõmbia, reconhecem baixos índices de notificação.]]></p></abstract>
<abstract abstract-type="short" xml:lang="fr"><p><![CDATA[Résumé  Objectif: Procéder á une revue de littérature des connaissances sur la pharmacovigilance et la fourniture d&#8217;informations sur la suspicion de Réactions Indésirables aux Médicaments (RIM), qui est autant un devoir moral pour le médecin et pour d&#8217;autres professionnels de la santé qu&#8217;un aspect des soins aux patients, ainsi que sur la sous-déclaration.  Matériaux et méthodes: La revue a été réalisée á l&#8217;aide des bases de données LILACS, PAHO, SciELO, EMBASE, PubMed et INFOMED, et des moteurs de recherche Google et Google Scholar, en utilisant des mots clés pour chercher des informations dans des articles originaux, théses, articles de revue de littérature et revues ayant des indices de citations élevés, publiés entre 1937 et 2017, en espagnol ou en anglais.  Résultats: 100 articles ont été identifiés, dont 30 ont été sélectionnés comme utiles pour actualiser les concepts en relation avec les disciplines impliquées dans la pharmacovigilance. Dans la pratique clinique, plusieurs facteurs peuvent entraver la détection des RIM et, par conséquent, contribuer á la sous-déclaration.  Conclusions: La sous-déclaration en pharmacovigilance est une réalité mondiale. Dans la plupart des publications analysées provenant d&#8217;Europe (Allemagne, Espagne et Royaume-Uni) et des pays d&#8217;Amérique latine comme la Colombie, on a pu observer la reconnaissance d&#8217;un faible taux de déclaration.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Infranotificación]]></kwd>
<kwd lng="es"><![CDATA[reacción adversa a medicamentos]]></kwd>
<kwd lng="es"><![CDATA[farmacovigilancia]]></kwd>
<kwd lng="es"><![CDATA[notificación]]></kwd>
<kwd lng="en"><![CDATA[Underreporting]]></kwd>
<kwd lng="en"><![CDATA[adverse drug reaction]]></kwd>
<kwd lng="en"><![CDATA[pharmacovigilance]]></kwd>
<kwd lng="en"><![CDATA[notification]]></kwd>
<kwd lng="pt"><![CDATA[Subnotificação]]></kwd>
<kwd lng="pt"><![CDATA[reação adversa a medicamentos]]></kwd>
<kwd lng="pt"><![CDATA[farmacovigilãncia]]></kwd>
<kwd lng="pt"><![CDATA[notificação]]></kwd>
<kwd lng="fr"><![CDATA[Sous-déclaration]]></kwd>
<kwd lng="fr"><![CDATA[Réaction indésirable aux médicaments]]></kwd>
<kwd lng="fr"><![CDATA[Pharmacovigilance]]></kwd>
<kwd lng="fr"><![CDATA[Notification]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sánchez]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
<name>
<surname><![CDATA[Amador]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Plaza]]></surname>
<given-names><![CDATA[JC.]]></given-names>
</name>
<name>
<surname><![CDATA[Correa]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Amador]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Impacto clínico de un sistema de farmacovigilancia activa realizado por un farmacéutico en el reporte y subnotificación de reacciones adversas a medicamentos]]></article-title>
<source><![CDATA[Rev Med chile]]></source>
<year>2014</year>
<volume>142</volume>
<page-range>998-1005</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Munir]]></surname>
<given-names><![CDATA[Pirmohamed.]]></given-names>
</name>
<name>
<surname><![CDATA[James]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Shaun]]></surname>
<given-names><![CDATA[Meakin.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adverse drug reactions as cause of admission to Hospital: Propective Analysis of 18 820 Patients]]></article-title>
<source><![CDATA[BMJ]]></source>
<year>2004</year>
<volume>324</volume>
<page-range>15-9</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lazarou]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Pomeranz]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
<name>
<surname><![CDATA[Corey]]></surname>
<given-names><![CDATA[PN.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Incidcnce of adverse drug rcactions in hospitalizcd paticnts: a metaanalysis of prospective studies]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>1988</year>
<volume>279</volume>
<page-range>1200-5</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nogereda Moreno]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Diaz Rosselló]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Causas de infranotificación de reacciones adversas a medicamentos en la comunidad autónoma de las Islas Baleares]]></article-title>
<source><![CDATA[Medicina Balear]]></source>
<year>2006</year>
<volume>21</volume>
<page-range>42-5</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="confpro">
<collab>OMS</collab>
<source><![CDATA[Ginebra]]></source>
<year>2016</year>
<conf-name><![CDATA[ Medicamentos, seguridad y reacciones adversas]]></conf-name>
<conf-loc> </conf-loc>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="">
<collab>WHO</collab>
<source><![CDATA[Geneve: Health Organization]]></source>
<year>2004</year>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rego]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Leyva]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez Sánchez]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pesquisaje activo de sospechas de reacciones adversas a medicamentos en el Hospital &#8220;Dr. Salvador Allende&#8221;]]></article-title>
<source><![CDATA[Rev Cubana Farm]]></source>
<year>2007</year>
<volume>41</volume>
<page-range>3</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Grootheest]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Graaf]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Jong]]></surname>
<given-names><![CDATA[V.]]></given-names>
</name>
<name>
<surname><![CDATA[L]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Consumer adverse drug reaction reporting: a new step in pharmacovigilance? Netherlands Pharmacovigilance Centre Lareb,&#8217;s- Hertogenbosch]]></article-title>
<source><![CDATA[The Netherlands]]></source>
<year>2013</year>
<volume>26</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>211-7</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="">
<collab>UCNFV</collab>
<source><![CDATA[Normas y procedimientos de trabajo del sistema cubano de farmacovigilancia]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Edwards]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[An agenda for UK clínica pharmacology Pharmacovigilance.]]></article-title>
<source><![CDATA[Br J Clin Pharmacol]]></source>
<year>2012</year>
<volume>73</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>979-82</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gil]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Amell]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Manrique]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[La farmacovigilancia aspectos generales y metodológicos]]></article-title>
<source><![CDATA[]]></source>
<year>2008</year>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sedeño]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Atención Farmacéutica y Farmacovigilancia]]></article-title>
<source><![CDATA[Revista Cubana Farm]]></source>
<year>2014</year>
<volume>14</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>28-32</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Morales]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Ruiz]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
<name>
<surname><![CDATA[Morgado]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[González]]></surname>
<given-names><![CDATA[X.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Farmacovigilancia en Chile y el mundo.]]></article-title>
<source><![CDATA[Rev chil infectol]]></source>
<year>2002</year>
<volume>19</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>S42-5</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Castillo]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<source><![CDATA[Conocimiento de farmacovigilancia y reporte de reacciones adversas]]></source>
<year>2014</year>
<publisher-loc><![CDATA[México ]]></publisher-loc>
<publisher-name><![CDATA[Universidad Veracruzana]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Reyes]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Farmacovigilancia en instituciones de salud]]></article-title>
<source><![CDATA[Revista Médica Sur México]]></source>
<year>2011</year>
<volume>18</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>102-11</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="confpro">
<collab>MINSAP</collab>
<source><![CDATA[Programa Nacional de Medicamentos de Cuba]]></source>
<year>2014</year>
<conf-name><![CDATA[ Formulario Nacional de Medicamentos]]></conf-name>
<conf-loc> </conf-loc>
<page-range>2-6</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="confpro">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Valsecia]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<source><![CDATA[UNNE]]></source>
<year>2015</year>
<conf-name><![CDATA[ Farmacoepidemiología y Farmacovigilancia: conceptos]]></conf-name>
<conf-loc> </conf-loc>
<publisher-loc><![CDATA[Argentina ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jiménez López]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Debesa García]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[González Delgado]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
<name>
<surname><![CDATA[Ávila Pérez]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez Peña]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[El Sistema Cubano de farmacovigilancia: seis años de experiencia en la detección de efectos adversos.]]></article-title>
<source><![CDATA[Rev Cubana Farm]]></source>
<year>2006</year>
<volume>40</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kyonen]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Folatre]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
<name>
<surname><![CDATA[Lagos]]></surname>
<given-names><![CDATA[X.]]></given-names>
</name>
<name>
<surname><![CDATA[Vargas]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparación de dos métodos de evaluación de causalidad de sospechas de reacciones adversas a medicamentos]]></article-title>
<source><![CDATA[Rev. méd. Chile]]></source>
<year>2009</year>
<volume>143</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>880-6</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="">
<collab>UNCB</collab>
<source><![CDATA[Desarrollo de fármacos y regulaciones sobre medicamentos]]></source>
<year>2015</year>
</nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="">
<collab>SCNFV</collab>
<source><![CDATA[Acciones a desarrollar en el sistema cubano de Farmacovigilancia para notificar una sospecha de reacción adversa a medicamentos]]></source>
<year>2014</year>
</nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Debesa García]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Jiménez]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez Peña]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Vigilancia farmacológica internacional en cuba]]></article-title>
<source><![CDATA[Situación actual]]></source>
<year>2010</year>
</nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Amariles]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Hincapié]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Jiménez]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Gutiérrez]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Giraldo]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Farmacoseguridad: farmacovigilancia y seguimiento farmacoterapéutico.]]></article-title>
<source><![CDATA[Rev Medellín]]></source>
<year>2011</year>
</nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="">
<collab>Ministerio de Salud Pública</collab>
<source><![CDATA[Acciones a desarrollar en el sistema cubano de Farmacovigilancia para notificar una sospecha de reacción adversa a medicamentos]]></source>
<year>2003</year>
<volume>01</volume>
</nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kyonen]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Folatre]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
<name>
<surname><![CDATA[Lagos]]></surname>
<given-names><![CDATA[X.]]></given-names>
</name>
<name>
<surname><![CDATA[Vargas]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparación de dos métodos de evaluación de causalidad de sospechas de reacciones adversas a medicamentos (RAM)]]></article-title>
<source><![CDATA[Rev. méd. Chile]]></source>
<year>2009</year>
</nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="confpro">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Valsecia]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<source><![CDATA[UNNE]]></source>
<year>2005</year>
<conf-name><![CDATA[ Farmacoepidemiología y farmacovigilancia: conceptos]]></conf-name>
<conf-loc> </conf-loc>
</nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="confpro">
<person-group person-group-type="author">
<name>
<surname><![CDATA[N]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
</person-group>
<source><![CDATA[Folleto de Conferencias de Farmacoterapia]]></source>
<year>2015</year>
<conf-name><![CDATA[ Reacciones adversas a medicamentos]]></conf-name>
<conf-loc> </conf-loc>
</nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fernando]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[Miguel]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Ortiz]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<source><![CDATA[Clasificación de las RAM CIOSM]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="confpro">
<collab>WHO</collab>
<source><![CDATA[The importance of pharmacovigilance]]></source>
<year>2002</year>
<conf-name><![CDATA[ World Health Organization &amp; WHO Collaborating Centre for International Drug Monitoring]]></conf-name>
<conf-loc> </conf-loc>
</nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="confpro">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alfonso]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
</person-group>
<source><![CDATA[Reacciones adversas a los antimicrobianos]]></source>
<year>2014</year>
<conf-name><![CDATA[ Sistema Cubano de Farmacovigilancia, 2003-2012]]></conf-name>
<conf-loc> </conf-loc>
</nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zamora]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Bess]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Zamora]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Validación de un cuestionario para evaluar causas administrativas de la baja notificación de reacciones adversas a los medicamentos]]></article-title>
<source><![CDATA[Rev Panam Salud Publica]]></source>
<year>2016</year>
<volume>39</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>352-7</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
